Non-invasive Prenatal Testing Market Outlook From USD 4.7 Bn in 2024 to USD 13.2 Bn by 2035 | TMR Report

Based on end-user, the global non-invasive prenatal testing market has been divided into hospitals, diagnostic laboratories, specialty clinics, and others.



Non-invasive Prenatal Testing Market

WILMINGTON, DE, UNITED STATES, August 26, 2025 /EINPresswire.com/ -- The global Non-invasive Prenatal Testing (NIPT) market, valued at USD 4.7 billion in 2024, is projected to reach USD 13.2 billion by 2035, expanding at a CAGR of 9.5% from 2025 to 2035. This growth is driven by rising awareness of early genetic screening, advancements in genomic technologies, increasing maternal age, and the growing preference for safe, accurate, and non-invasive testing methods over traditional procedures.

Rising prevalence of Down syndrome cases and growing maternal age and associated chromosomal risks are driving the non-invasive prenatal testing market demand. Moreover, physicians are choosing advanced DNA-based screening methods like NIPT due to their high safety, accuracy, and early screening for chromosomal abnormalities in pregnancy.

> “Non-invasive Prenatal Testing Market to Reach USD 13.2 Bn by 2035”
>
> *Transparency Market Research Inc.*

Dive Deeper into Data: Get Your In-Depth Sample Now!
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=374

Non-invasive Prenatal Testing, or NIPT, is a test performed during pregnancy to asess the risk of certain genetic conditions in a fetus. It is performed by analysing small fragments of fetal DNA in the mother's blood, usually as early as week 10 of pregnancy. Unlike invasive procedures such as

amniocentesis or chorionic villus sampling (CVS), NIPT is not harmful to the fetus in any way because it is just a routine blood test on the mother.

Compared to invasive testing procedures like amniocentesis with a risk of complications, NIPT is a non-invasive testing procedure that provides accurate findings, making it a procedure of choice among physicians and expectant couples alike.

□□□□□□ □□□□□□□□□□□□

□□□ □□□□ □□□□□□ □□□ □□ □□□□□□□□□ □□□□□ □□ □□□□□□□ □□□ □□□□□□□:

□□ □□□□□□□ □□□□:

Cell-Free DNA Screening: This is the largest and most dominant segment, as it's the core technology behind NIPT. It involves analyzing cfDNA from maternal blood to detect chromosomal abnormalities.

Biochemical Marker Screening: This involves analyzing specific proteins and hormones in the mother's blood to assess the risk of certain conditions. While less accurate than cfDNA, it's a complementary or alternative screening method.

Ultrasound Screening: This is another non-invasive method often used in conjunction with NIPT to screen for structural abnormalities.

By Sourcing Type:

In-house: Testing performed within a company's own laboratory.

Outsourced: Samples sent to a third-party diagnostic laboratory for analysis.

□□ □□□□□□□□□□□:

Trisomy Detection: The largest application segment, primarily for screening Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13).

Microdeletion Screening: A growing segment for detecting smaller chromosomal deletions that can lead to various genetic disorders.

Sex Chromosome Aneuploidies: Screening for conditions like Turner syndrome and Klinefelter syndrome.

Other Applications: This includes screening for single-gene disorders, among other conditions.

□□ □□□□□□□□ □□□□□□□□□/□□□ □□□□:

Diagnostic Laboratories: The primary end-users, where the majority of NIPT tests are processed.

Hospitals and Birthing Centers: These facilities act as a primary point of contact for patient samples and counseling.

Research Institutes: These institutions are involved in developing new NIPT applications and technologies.

□□ □□□□□□:

North America: Dominates the market with the largest share, thanks to advanced healthcare infrastructure, high healthcare spending, and a strong presence of key market players. The US alone is a major hub for innovation and commercialization.

Europe: The second-largest market, with a significant push from government reimbursement policies in countries like the Netherlands and Germany, which have made NIPT a publicly funded option.

Asia Pacific: This region is projected to be the fastest-growing market, driven by a large patient population, rising disposable incomes, and increasing awareness of advanced prenatal care.

Latin America and the Middle East & Africa: These regions are also experiencing growth, albeit from a smaller base, due to improving healthcare infrastructure and growing awareness.

□□□□□□□□ □□□□□□□□

North America is expected to maintain its lead in the NIPT market, holding a significant share driven by favorable reimbursement policies and a high adoption rate. Europe continues to be a strong market due to widespread clinical acceptance and growing public awareness. The Asia Pacific region, particularly countries like China and India, represents a major growth opportunity with increasing healthcare expenditure and a large number of births.

□□□□□□ □□□□□□□ □□□ □□□□□□□□□□

□□□□□□ □□□□□□□ □:

Rising Maternal Age: The global trend of women having children later in life increases the risk of chromosomal abnormalities, driving the demand for NIPT.

High Accuracy and Safety: NIPT offers superior accuracy for detecting common trisomies

compared to traditional screening methods, with the added benefit of being non-invasive and risk-free for the fetus.

Growing Awareness: Increased awareness among expectant parents and healthcare professionals about the benefits and availability of NIPT is boosting its adoption.

Technological Advancements: Continuous improvements in NGS and bioinformatics have led to more accurate, faster, and affordable tests, expanding their use.

□□□□□□ □□□□□□□□□□ □:

High Cost: Despite technological advancements, the cost of NIPT can still be a barrier for many, especially in developing regions where insurance coverage is limited.

Ethical and Regulatory Concerns: Issues surrounding the use of NIPT for sex selection or the detection of incidental findings raise ethical dilemmas and create regulatory complexities.

Limited Infrastructure: A lack of specialized laboratory infrastructure and bioinformatics expertise in some emerging markets can hinder market expansion.

□□□□□□ □□□□□□

Expanded NIPT Panels: A major trend is the shift from screening only for common trisomies to offering expanded panels that include microdeletions, single-gene disorders, and other genetic conditions.

Decreasing Cost of Sequencing: The cost of NGS continues to fall, making NIPT more accessible and leading to higher adoption rates.

Adoption for Low-Risk Pregnancies: Initially used for high-risk pregnancies, NIPT is increasingly being recommended for all pregnancies, including those considered low-risk.

Artificial Intelligence (AI) in Diagnostics: The integration of AI and machine learning is enhancing the accuracy and speed of interpreting NIPT results, particularly for complex chromosomal anomalies.

□□□□□□ □□□□□□□

The future of the NIPT market is exceptionally promising. We can expect to see wider adoption, driven by declining costs, favourable reimbursement policies, and continued technological innovation. The market will likely become more integrated into routine prenatal care globally. Furthermore, the expansion of NIPT to include a broader range of genetic disorders and the potential for direct-to-consumer services will open up new avenues for growth.

□□□ □□□□□□□ □□□□□ □□□□□□□

The market is largely dominated by cell-free DNA-based testing, which is expected to hold the highest share throughout the forecast period.

Next-generation sequencing (NGS) is the leading technology, providing the highest accuracy and contributing significantly to market growth.

Trisomy detection, especially for Down syndrome, remains the most prevalent application.

North America and Europe will remain key markets, while the Asia Pacific region will be the fastest-growing.

□□□□□□□□□□□ □□□□□□□□□□

The NIPT market is a highly competitive and consolidated space, with several key players vying for market share. These companies are focused on product innovation, strategic collaborations, and expanding their geographic footprint.

□□□ □□□□ □□□□□□□ □□□□□□□□ □□□□□□:
https://www.transparencymarketresearch.com/checkout.php?rep_id=374&ltype=S

□□□ □□□□□□□ □□□□□□□:

Berry Genetics
BGI
Laboratory Corporation of America Holdings
Agilent Technologies, Inc.
Illumina, Inc.
F. Hoffmann-La Roche Ltd.
NATERA, INC.
PerkinElmer Inc.
Eurofins SCientific
IGENOMIX
Other Players

□□□□□□ □□□□□□□□□□□□

February 2025: Yourgene Health (a Novacyt group company) launched IONA Care+ in the UK, using its IONA Nx NIPT Workflow for safe and accurate testing, aiming to reduce the need for invasive procedures.

May 2024: Natera, Inc. announced the launch of a new cfDNA-based fetal RhD test, providing a timely solution to a nationwide shortage of Rho(D) immune globulin therapy.

April 2025: VeriSeq, a European diagnostics firm, reduced the average cost per NIPT test by 18% after implementing newer, high-throughput NGS platforms, enabling partnerships with mid-sized clinics.

□□□□□□□□ □□□□□□□ □□□□□□□□□ □□□□□□□□ □□ □□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□:

Testing and Analysis Services Market - https://www.transparencymarketresearch.com/testing-analysis-services-market.html

In Vitro Toxicity Testing Market - https://www.transparencymarketresearch.com/in-vitro-toxicity-testing-market.html

Non-Destructive Testing Equipment Market - https://www.transparencymarketresearch.com/nondestructive-testing-equipment.html

Microbiology Culture Market - https://www.transparencymarketresearch.com/microbiology-culture-market.html

Transplant Diagnostics Market - https://www.transparencymarketresearch.com/transplant-diagnostics-market.html

Cancer Diagnostics Market - https://www.transparencymarketresearch.com/cancer-diagnostics-market.html

Carrier Screening Market - https://www.transparencymarketresearch.com/carrier-screening-market-report.html

UAE Clinical Laboratory Services Market - https://www.transparencymarketresearch.com/uae-clinical-laboratory-services-market.html

Syphilis Immunoassay Diagnostics Market - https://www.transparencymarketresearch.com/syphilis-diagnostics-market.html

Lung Cancer Diagnostics Market- https://www.transparencymarketresearch.com/lung-cancer-diagnostics-market.html

Metabolomics Market - https://www.transparencymarketresearch.com/metabolomics-market.html

Hemostasis Products Market - https://www.transparencymarketresearch.com/hemostasis-

products-market.html

□□□□□ □□□□□□□□□□□□ □□□□□□ □□□□□□□□

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

□□□□□□□:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter| Blog | YouTube

Atil Chaudhari
Transparency Market Research Inc.
+1 518-618-1030
email us here
Visit us on social media:
LinkedIn
Instagram
YouTube
X
